Skip to main
ESLA
ESLA logo

ESLA Stock Forecast & Price Target

ESLA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Estrella Immunopharma is advancing its EB104 dual CD19/CD22 program, which has shown promising results, including a favorable safety profile and a complete response in one patient, indicating the potential efficacy of its therapies in treating B-cell malignancies and autoimmune indications. The company's strategic move into a higher dose cohort strengthens its position within the evolving T-cell therapy market and enhances its development prospects. Furthermore, the innovative Artemis Technology platform may unlock new market opportunities in immunology and solid tumor treatments, reinforcing the positive outlook on Estrella's long-term growth potential in the biopharmaceutical sector.

Bears say

The financial outlook for Estrella Immunopharma appears negative due to the lack of substantial revenue generation from its current clinical-stage pipeline, which is still in the early phases of development for addressing B-cell Non-Hodgkin’s Lymphomas. Additionally, the repetitive financial data presented for the target market in China indicates a more speculative growth potential rather than immediate financial viability, as it highlights an absence of current cash flow from approved products. Furthermore, without confirmed clinical success and regulatory approvals, the company's ability to capture a portion of the estimated market growth and translate it into meaningful financial performance remains uncertain.

ESLA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Estrella Immunopharma Inc (ESLA) Forecast

Analysts have given ESLA a Strong Buy based on their latest research and market trends.

According to 1 analysts, ESLA has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Estrella Immunopharma Inc (ESLA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.